Amgen Inc
USUSDAmgen Inc (US:AMGN) — Biotechnology: Biological Products (No Diagnostic Substances). Nombre de places boursières sur lesquelles les actions de la société sont cotées : 4. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.
À propos de l'entreprise
- Site web
- amgen.com
- Relations avec les investisseurs
- investors.amgen.com/
- Secteur
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Siège social
- Thousand Oaks, United States
- PDG
- Robert A. Bradway
- Employés
- 17 900
- Fondée
- 1980
- Actions en circulation
- 540.63 M au 2026-07-30
- Flottant
- 539.16 M
- Capitalisation boursière
- 226.05 Md USD
- Initiés
- 0.23%
- Investisseurs institutionnels
- 85.02%
- Secteur d'activité (SIC)
- Biological Products, (No Diagnostic Substances)
- Forme juridique
- XTIQ
- ISIN
- US0311621009
- LEI
- 62QBXGPJ34PQ72Z12S66
- Taux de distribution
- 60.4%
- FCF
- 10.2 Md USD52%
- Dette
- 57.3 Md USD4.3 ans de FCF
- Ancienneté du dividende
- 15 ans
- Bénéfices, FCF et dividendes versés — pour les 12 mois précédant 30.06.2026 (le dernier rapport de l'entreprise).
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Bourses et tickers
| Bourse | Ticker | Devise | Prix | Type |
|---|---|---|---|---|
| US USA Stocks | AMGN principale | USD | 407.44 -1.37% | actions ordinaires |
| HK Hong Kong Stock Exchange | 4332 secondaire | HKD | — | |
| LSE London Stock Exchange | 0R0T IOB | USD | 411.854 +1.17% | actions ordinaires |
| MX Mexican Stock Exchange | AMGN secondaire | MXN | 7 500.0098 +0.00% | actions ordinaires |
| XETRA Xetra | AMG secondaire | EUR | 367.95 -1.39% | actions ordinaires |
Dividendes
Amgen Inc (AMGN) verse des dividendes trimestriels. Au cours des 12 derniers mois, 9.94 USD par action ont été versés (versements : 4). Cela représente environ 2.44% du cours actuel de l'action. D'après l'historique des paiements, la prochaine date ex-dividende est prévue vers 20.11.2026. Historique des dividendes ininterrompu : 15 ans.
| Date ex | Versement | Montant | % | Type | Ticker |
|---|---|---|---|---|---|
| 2026-08-21 | 2026-09-11 | 2.5200 USD | 0.6/2.4 % | trimestriel | US:AMGN |
| 2026-05-15 | 2026-06-05 | 2.5200 USD | 0.6/2.4 % | trimestriel | US:AMGN |
| 2026-02-13 | 2026-03-06 | 2.5200 USD | 0.6/2.4 % | trimestriel | US:AMGN |
| 2025-11-21 | 2025-12-12 | 2.3800 USD | 0.6/2.3 % | trimestriel | US:AMGN |
| 2025-08-22 | 2025-09-12 | 2.3800 USD | 0.6/2.3 % | trimestriel | US:AMGN |
| 2025-05-16 | 2025-06-06 | 2.3800 USD | 0.6/≈2.3 % | trimestriel | US:AMGN |
| 2025-02-14 | 2025-03-07 | 2.3800 USD | 0.6/≈2.3 % | trimestriel | US:AMGN |
| 2024-11-18 | 2024-12-09 | 2.2500 USD | 0.6/≈2.2 % | trimestriel | US:AMGN |
Actualités de cette semaine
Pas encore d'actualités du site de l'entreprise.
Principaux actionnaires
| Détenteur | Participation | Actions | Date du rapport |
|---|---|---|---|
| Blackrock Inc. | 9.13% | 49.36 M | 2026-06-30 |
| Vanguard Capital Managem… | 6.52% | 35.25 M | 2026-06-30 |
| State Street Corporation | 5.65% | 30.56 M | 2026-06-30 |
| Capital World Investors | 5.38% | 29.08 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 17.13 M | 2026-06-30 |
| Invesco Ltd. | 3.02% | 16.32 M | 2026-06-30 |
| Geode Capital Management… | 2.9% | 15.7 M | 2026-06-30 |
| Charles Schwab Investmen… | 2.78% | 15.03 M | 2026-06-30 |
| Vanguard Portfolio Manag… | 2.75% | 14.85 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 13.99 M | 2026-06-30 |
| Morgan Stanley | 2.53% | 13.65 M | 2026-06-30 |
| Invesco QQQ Trust, Serie… | 2.15% | 11.61 M | 2026-08-31 |
| SCHWAB STRATEGIC TRUST-S… | 1.81% | 9.79 M | 2026-05-31 |
| Income Fund of America | 1.44% | 7.76 M | 2026-06-30 |
| iShares Trust-iShares Co… | 1.35% | 7.28 M | 2026-07-31 |
| Wells Fargo & Company | 1.34% | 7.24 M | 2026-06-30 |
| AMERICAN BALANCED FUND | 1.31% | 7.09 M | 2026-06-30 |
| Fidelity Concord Street… | 1.29% | 6.98 M | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.22% | 6.6 M | 2026-08-31 |
| WASHINGTON MUTUAL INVEST… | 1.16% | 6.27 M | 2026-06-30 |
| BRADWAY ROBERT A (Chief… | ≈0.12% | 657 299 | 2026-05-05 |
| SANTOS ESTEBAN (Officer) | ≈0.02% | 84 279 | 2026-05-05 |
| GORDON MURDO (Officer) | ≈0.01% | 51 837 | 2026-05-05 |
| GRIFFITH PETER H. (Chief… | ≈0.01% | 50 706 | 2026-05-05 |
| REESE DAVID M. (Chief Te… | ≈0.01% | 42 812 | 2026-05-05 |
| GRAHAM JONATHAN P (Gener… | ≈0.01% | 40 211 | 2026-05-05 |
| BRADNER JAMES E. (Office… | ≈0.01% | 30 462 | 2026-05-05 |
| ECKERT ROBERT ANDREW (Di… | ≈0% | 26 251 | 2026-05-19 |
| JACKS TYLER (Director) | ≈0% | 18 284 | 2026-05-19 |
| KULLMAN ELLEN JAMISON (D… | ≈0% | 14 536 | 2026-05-19 |
